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Abstract
Background: Non-organ specific autoantibodies are highly prevalent in patients with chronic hepatitis C (HCV). Among
them, anti-liver kidney microsomal type 1 (LKM1) antibody – the serological marker of type 2 autoimmune hepatitis
(AIH-2)- is detected in up to 11% of the HCV-infected subjects. On the other hand, anti-liver cytosol type 1 antibodies
(anti-LC1) – either in association with anti-LKM1, or in isolation- and anti-soluble liver antigen antibodies (anti-SLA) have
been considered as useful and specific diagnostic markers for AIH. However, their specificity for AIH has been questioned
by some recent studies, which have shown the detection of anti-LC1 and anti-SLA by immunoprecipitation assays in HCV
patients irrespective of their anti-LKM1 status. The aim of the present study was to test the anti-LC1 and anti-SLA
presence by specific enzyme linked immunosorbent assays (ELISAs), in a large group of Greek HCV-infected patients with
or without anti-LKM1 reactivity as firstly, immunoprecipitation assays are limited to few specialized laboratories
worldwide and cannot be used routinely and secondly, to assess whether application of such tests has any relevance in
the context of patients with viral hepatitis since antibody detection based on such ELISAs has not been described in detail
in large groups of HCV patients.
Methods: One hundred and thirty eight consecutive HCV patients (120 anti-LKM1 negative and 18 anti-LKM1 positive)
were investigated for the presence of anti-LC1 and anti-SLA by commercial ELISAs. A similar number (120) of chronic
hepatitis B virus (HBV) infected patients seronegative for anti-LKM1 was also tested as pathological controls.
Results: Six out of 18 (33%) anti-LKMpos/HCVpos patients tested positive for anti-LC1 compared to 1/120 (0.83%) anti-
LKMneg/HCVpos patients and 0/120 (0%) of the anti-LKM1neg/HBVpos patients (p < 0.001 for both comparisons). Anti-SLA
antibodies were not present in any of the HCV (with or without anti-LKM1) or HBV-infected patients.
Conclusion: We showed that anti-LC1 and anti-SLA autoantibodies are not detected by conventional assays in a large
group of anti-LKM1 negative patients with chronic hepatitis B and C infections. Based on these results we cannot find
any justification for the application of anti-LC1 and anti-SLA tests in the routine laboratory testing of viral hepatitis-
related autoantibody serology with the only potential exception being the anti-LC1 screening in anti-LKM1pos/HCVpos
patients.
Published: 4 February 2007
Journal of Autoimmune Diseases 2007, 4:2 doi:10.1186/1740-2557-4-2
Received: 19 October 2006
Accepted: 4 February 2007
This article is available from: http://www.jautoimdis.com/content/4/1/2
© 2007 Rigopoulou et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Autoimmune Diseases 2007, 4:2 http://www.jautoimdis.com/content/4/1/2
Page 2 of 6
(page number not for citation purposes)
Background
Non-organ specific autoantibodies (NOSA), particularly
smooth muscle antibodies (SMA) and antinuclear (ANA)
antibodies are highly prevalent in patients with chronic
hepatitis C virus (HCV) infection [1-7]. Anti-liver kidney
microsomal type 1 (LKM1) antibody – the serological
marker of type 2 autoimmune hepatitis (AIH-2)- is also
detected in up to 11% of the HCV-infected subjects [1,8-
11]. Anti-liver cytosol type 1 (LC1) antibodies have origi-
nally been described either in association with anti-LKM1,
or in isolation, and in both instances define a clinical
entity indistinguishable from AIH-2 [12,13]. Anti-LC1 has
also been found occasionally in anti-LKM1 positive
chronic hepatitis C virus (HCV) infected patients [10,14].
Detection of anti-soluble liver antigen antibodies (anti-
SLA) was initially considered to identify a third type of
AIH seronegative for the conventional ANA, SMA, anti-
LKM1 autoantibodies [15] but recent studies indicate that
it can also be present in conjunction with other AIH-spe-
cific antibodies suggesting that anti-SLA is rather an addi-
tional important marker for the diagnosis of type 1 AIH,
than a marker of a third type of AIH [11,16-19].
Hence, anti-LC1 and anti-SLA autoantibodies appear use-
ful diagnostic markers for AIH but their accurate detection
was until recently hampered by the fact that anti-LC1 is
obscured by the concurrent presence of anti-LKM1 using
the indirect immunofluorescence (IIFL) routine screen-
ing, while anti-SLA are undetectable by IIFL [9-11]. In
recent years, the molecular targets of anti-LC1 and anti-
SLA have been identified as formiminotransferase cycl-
odeaminase (FTCD) and UGA tRNA suppressor associ-
ated antigenic protein (tRNP(Ser)Sec), respectively and
commercial enzyme linked immunosorbent assay
(ELISA) kits for their detection have become available
[9,20-25]. Their specificity for AIH, however, has been
questioned by studies from the group of Alvarez [26,27].
By immunoprecipitation of radiolabeled human FTCD,
Beland et al have found that anti-FTCD antibodies are
present in 10% of anti-LKM1 positive and 15% of anti-
LKM1 negative chronic HCV infected patients [26]. Of
interest and using a similar approach, the same group has
detected anti-SLA antibodies in 28% of anti-LKM1 posi-
tive and in 12% of anti-LKM1 negative HCV infected
patients [27]. These findings challenge the prevailing
notion that antibodies against human FTCD and
tRNP(Ser)Sec are highly specific for autoimmune liver dis-
eases [20-25,28,29]. According to the authors of the
abovementioned studies [26,27], anti-LC1 and anti-SLA
autoantibodies can be regarded as serological markers of
autoimmunity and need to be tested when investigating
autoimmunity, especially in chronic HCV infection.
Immunoprecipitation assays, however, are limited to few
specialized laboratories worldwide and cannot be used
routinely. Indeed, most of the non-specialized laborato-
ries have started making use of kit-based semi-automated
commercial anti-LC1 and anti-SLA ELISAs. The question
as to whether application of such tests has any relevance
in the context of patients with viral hepatitis still remains
unanswered, as antibody detection based on such ELISAs
has not been described in detail in large groups of patients
with chronic viral hepatitis B and C.
The aim of the present study was to test anti-FTCD (anti-
LC1) and anti-tRNP(Ser)Sec (anti-SLA) antibodies, in a large
number of Greek HCV-infected patients with or without
anti-LKM1 seropositivity. A similar number of chronic
hepatitis B virus (HBV) infected patients was also tested as
pathological controls. We were able to show that there is
no reason for additional routine laboratory testing for
anti-LC1 and anti-SLA antibodies in HCV-infected
patients unless there are anti-LKM1 antibodies present.
Methods
Patients
One hundred and twenty consecutive patients with
chronic hepatitis C (mean age 47 ± 12.3 standard devia-
tion (SD) years; 62 female), seronegative for anti-LKM1
(anti-LKMneg/HCVpos) by IIFL followed at the Department
of Medicine, Academic Liver Unit, University of Thessaly
Medical School were studied. The diagnosis of chronic
HCV infection was based on: (a) detection of anti-HCV
antibodies using a third-generation ELISA (Murex Diag-
nostics, Temple Hill, Dartford, UK) at least twice within 6
months before their enrolment into the study; and (b)
active virus replication as defined by the detection of HCV
RNA using a commercially available qualitative PCR kit
(HCV Monitoring Cobas Amplicor, Roche, Geneva, Swit-
zerland), as described previously [1,2,30]. At the time of
serum sample collection, 45 patients had completed anti-
viral treatment with alpha-interferon (IFN-a) alone or in
combination with ribavirin. All patients were negative for
the following viral markers tested using commercial kits
(Abbott Diagnostic Kits, North Chicago, IL, USA): Hepati-
tis B surface Antigen (HBsAg), anti-HBsAg antibody (anti-
HBs), anti-Hepatitis B core antibody (anti-HBc), and anti-
human immunodeficiency virus (anti-HIV, VIDAS
HIVDUO Bio MER©IEUX, Marcy-l'Etoile, France). Histo-
logical, serological and clinical details of these patients
have been described in previous reports [1,2,30]. The
results obtained by ELISA testing of the anti-LKM1 nega-
tive patients with hepatitis C were compared to those
obtained by testing of 18 anti-LKM1pos/HCVpos patients
(mean age 47 ± 11.3 years; 12 female) and 120 anti-
LKM1neg/HBVpos Greek patients (mean age 49.1 ± 11.2; 81
male) all HBV-DNA positive by a sensitive PCR kit (HBV
Monitor Cobas Amplicor, Roche; cut-off: 200 copies/ml)
and negative for HCV markers.Journal of Autoimmune Diseases 2007, 4:2 http://www.jautoimdis.com/content/4/1/2
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Autoantibody detection
Presence of ANA, SMA, anti-LKM1, anti-LC1 and anti-
mitochondrial antibodies was initially detected by IIFL on
5 μm frozen sections of in-house rodent multi-organ (kid-
ney, liver and stomach) tissue substrates using as revealing
reagent an anti-total human IgG fluorescein isothiocy-
anate conjugate (Dako Ltd, High Wycombe, Bucks, UK),
as previously described [1,9]. Briefly, diluted sera (1/40)
in phosphate buffered saline (PBS) were tested on in-
house snap-frozen sections of rat liver, kidney and stom-
ach. Positive sera were titred by double dilution to extinc-
tion. The patterns of reactivity were assessed under a
fluorescence microscope (Orthoplan, Leitz, Wetzlar, Ger-
many). Anti-LKM1, anti-LC1 and anti-SLA reactivity was
also evaluated by Western immunoblotting using both
human microsomal and cytosolic fraction as antigen
sources (Euroimmun, Lübeck, Germany). Commercially
available ELISA (Euroimmun) were used for the detection
of anti-FTCD (anti-LC1) and tRNP(Ser)Sec  (anti-SLA)
autoantibodies, according to the manufacturer's instruc-
tions. Antibody binding titres expressed as optical density
(OD) testserum/OD calibrator and extinction values of serum
samples exceeding those of the calibrator (OD testserum/OD
calibrator > 1) were considered positive.
Inhibition studies
To investigate whether the 58–60 kDa band immunofixed
by anti-LC1 is FTCD, inhibition experiments were per-
formed using the anti-LC1 positive serum, diluted at 1/
200, and pre-incubated with solid phase recombinant
FTCD (Euroimmun), as previously described [31,32].
Each patient gave informed consent to participate in this
study. The Local Ethical Committee of The Medical
School, University of Thessaly approved the study proto-
col.
Statistical analysis
Data are presented as percentages (%) or mean ± SD
unless otherwise stated. The differences between different
groups were compared using t-test, the Mann Whitney U
test, χ2, (two by two with Yates' correction) and Fisher's
exact test as appropriate. Two-sided p values < 0.05 were
considered as statistically significant.
Results and discussion
Prevalence of various NOSA is summarised in Table 1.
Anti-FTCD (anti-LC1) antibodies were present in 6/18
(33%) anti-LKMpos/HCVpos compared to 1/120 (0.83%)
anti-LKMneg/HCVpos patients (a 47-years old male patient
at the third month of IFN-a treatment with no evidence of
aminotransferases flare and without history of extrahe-
patic immunopathological manifestations) and 0/120
(0%) of the anti-LKM1neg/HBVpos patients (p < 0.001 for
both; Figure 1A). By western blot using a human liver
cytosolic fraction as substrate, the anti-FTCD positive anti-
LKMneg/HCVpos case immunofixed a relatively weak 58–
60 kDa band corresponding to LC1 autoantigen (Figure 2,
lane 1). This band was almost completely abolished when
the reactive serum was pre-incubated with recombinant
FTCD as solid phase competitor (Figure 2, lane 2) indicat-
ing that is due to anti-FTCD reactivity. Repeat IIFL of this
case revealed absence of a pattern typical of anti-LC1;
there was no staining of cytoplasm of liver cells with rela-
tive sparing of the centrilobular area, even when the
serum was tested at dilution of 1/20.
Anti-tRNP(Ser)Sec (anti-SLA) antibodies were not present
in any of the HCV (with or without anti-LKM1 reactivity)
or HBV infected patients (Figure 1B). Similar data we have
obtained when an anti-SLA ELISA of another manufac-
turer (Inova Diagnostics, San Diego, California, USA) was
used (data not shown).
Chronic HCV infection is frequently characterized by an
altered immune homeostasis as it has become evident by
the high prevalence of NOSA, and in particular SMA and
ANA which, according to some reports, exceeds 50% of
the infected population [1-7]. Anti-LKM1 antibody – the
serological marker of type 2 AIH- is also detected in up to
11% of the HCV-infected subjects [1,8-11]. Under this
context, the detection of anti-LC1 and anti-SLA antibodies
in a significant proportion of HCV patients in the two
recent studies – irrespective of the anti-LKM1 status –
Table 1: Prevalence of non-organ specific autoantibodies detected by indirect immunofluorescence (IIFL) or enzyme linked 
immunosorbent assay (ELISA) in patients with chronic hepatitis C and B.
Anti-LKM1 (IIFL) Anti-LC1 (ELISA) Anti-SLA (ELISA) ANA (IIFL) SMA (IIFL)
LKM1pos/HCVpos 18/18 (100%)* 6/18 (33%) 0/18 (0%) 5/18 (27.7%)** 6/18 (33%)***
LKM1neg/HCVpos 0/120 (0%) 1/120 (0.8%) 0/120 (0%) 45/120 (37.5%)** 61/120 (50.8%)***
LKM1neg/HBVpos 0/120 (0%) 0/120 (0%) 0/120 (0%) 23/120 (19.2%)** 15/120 (12.5%)***
LKM1, liver kidney microsomal type 1; LC1, liver cytosol type 1; SLA, soluble liver antigen; ANA, anti-nuclear antibody; SMA, smooth muscle 
antibody; pos, positive; neg, negative; *Confirmed by Western immunoblotting (see Methods section); **Low titers of ANA were detected in the 
three groups (mean titer: 1/168, 1/148 and 1/140, respectively); ***Low titers of SMA were detected in the three groups (mean titer: 1/134, 1/121 
and 1/119, respectively).Journal of Autoimmune Diseases 2007, 4:2 http://www.jautoimdis.com/content/4/1/2
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[26,27] could not be a surprising finding as it might fur-
ther support the autoimmune propensity of the virus.
The findings of the present study however, suggest that
commercially available assays are unable to detect anti-
LC1 and anti-SLA antibodies in a large number of anti-
LKM1 negative patients either with chronic HCV or with
chronic HBV infection. On the contrary, we found that a
considerable proportion of anti-LKMpos/HCVpos patients
(33%) had detectable anti-LC1 antibodies by ELISA,
which is in accordance with previous studies from Italy
[14].
The question arises as to whether the inability of the
detection of anti-LC1 and anti-SLA antibodies by ELISAs
in patients with chronic HCV infection is due to the supe-
rior sensitivity of the immunoprecipitation assays used by
Beland et al [26] and Vitozzi et al [27]. Radioligand assays
of higher sensitivity than the conventional assays have
increasingly been reported in the autoantibody diagnostic
setting of a plethora of autoimmune diseases such as dia-
betes, multiple sclerosis, systemic lupus erythematosus
and AIH [1,28,33-38]. There are still some reservations
however, as to whether this is the sole reason for the dis-
crepant results between ELISAs and immunoprecipitation
assays specific for anti-LC1 and anti-SLA detection. First, it
has been generally agreed that as equipment becomes
more sophisticated, higher diagnostic sensitivity of an
assay frequently comes at the expense of a lower specifi-
city [38]. Beland et al [26] and Vitozzi et al [27] argue that
this cannot be the case for their immunoprecipitation
anti-LC1 and anti-SLA assays because they can detect these
autoantibodies in patients with chronic hepatitis C but
not in other pathological controls. These investigators, in
particular, were unable to detect anti-LC1 in any of the 22
patients with type 1 AIH or the 25 patients with other
unrelated chronic liver diseases (which however did not
describe in detail).
The focus of the present study was not the validation of
the findings of the French/Canadian group. We rather
decided to investigate the prevalence of anti-LC1 and anti-
(A). ELISA titers of anti-formimino-transferase cyclodeaminase (anti-FTCD) antibodies, known also as anti-liver cytosolic type  1 antibodies (anti-LC1) and (B) Figure 1
(A). ELISA titers of anti-formimino-transferase cyclodeaminase (anti-FTCD) antibodies, known also as anti-liver cytosolic type 
1 antibodies (anti-LC1) and (B). titers of anti-UGA tRNA suppressor associated antigenic protein (tRNP(Ser)Sec) antibodies, 
known also as anti-soluble liver antigen antibodies (anti-SLA) in 18 liver kidney microsomal type 1 (LKM1) positive chronic hep-
atitis C virus (HCV) infected patients; 120 LKM1 negative chronic HCV infected patients; and 120 LKM1 negative hepatitis B 
virus (HBV) infected patients. According to the manufacturer's instructions, autoantibody reactivity is considered positive 
when optical density (OD)test serum/ODcalibrator > 1.
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SLA in anti-LKM1neg/HCVpos patients by commercial ELI-
SAs and to test their diagnostic utility in the day-to-day
clinical practice. Our assumption has been based on the
fact that if anti-LC1 and anti-SLA are present in anti-
LKM1neg/HCVpos  patients and these antibodies can be
detected by routinely performed ELISAs, clinicians should
be aware and request for their detection. We have found
that neither anti-LC1 nor anti-SLA autoantibodies are
detectable in anti-LKM1 negative patients with chronic
viral hepatitis C or B by ELISAs.
Conclusion
We showed that anti-LC1 and anti-SLA autoantibodies are
not detected by conventional assays in the vast majority of
patients with chronic viral hepatitis B and C. Based on
these results we cannot find any justification for the appli-
cation of anti-LC1 and anti-SLA tests in the routine labo-
ratory testing of viral hepatitis-related autoantibody
serology unless anti-LKM1 antibodies are present in HCV-
infected patients. In the latter case, only anti-LC1 screen-
ing could be of interest. Exchange of sera and standardiza-
tion of the methodology employed, whether it is
radioligand, western blot or ELISA is urgently warranted
to address definitely whether anti-LC1 and anti-SLA
autoantibodies are serological markers of chronic hepati-
tis C.
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